Jeroen Dekervel

3.3k total citations
69 papers, 1.1k citations indexed

About

Jeroen Dekervel is a scholar working on Oncology, Epidemiology and Hepatology. According to data from OpenAlex, Jeroen Dekervel has authored 69 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 18 papers in Epidemiology and 16 papers in Hepatology. Recurrent topics in Jeroen Dekervel's work include Hepatocellular Carcinoma Treatment and Prognosis (15 papers), Neuroendocrine Tumor Research Advances (14 papers) and Neuroblastoma Research and Treatments (11 papers). Jeroen Dekervel is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (15 papers), Neuroendocrine Tumor Research Advances (14 papers) and Neuroblastoma Research and Treatments (11 papers). Jeroen Dekervel collaborates with scholars based in Belgium, United States and France. Jeroen Dekervel's co-authors include Chris Verslype, Eric Van Cutsem, Jos van Pelt, Petra Windmolders, Hannah van Malenstein, Frederik Nevens, Diether Lambrechts, Christophe M. Deroose, Frederik Cleeren and Elin Pauwels and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Jeroen Dekervel

60 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeroen Dekervel Belgium 18 617 316 239 230 165 69 1.1k
Yusuke Mitsunori Japan 19 435 0.7× 417 1.3× 223 0.9× 247 1.1× 88 0.5× 40 1.0k
Roberto Carmagnani Pestana United States 17 547 0.9× 217 0.7× 119 0.5× 192 0.8× 125 0.8× 52 1.1k
Xinyu Bi China 17 480 0.8× 361 1.1× 216 0.9× 245 1.1× 110 0.7× 100 1.2k
Bin Meng China 18 334 0.5× 245 0.8× 133 0.6× 141 0.6× 151 0.9× 62 814
Antonella Argentiero Italy 23 794 1.3× 596 1.9× 162 0.7× 427 1.9× 149 0.9× 48 1.6k
Susanna V. Ulahannan United States 17 524 0.8× 324 1.0× 217 0.9× 168 0.7× 106 0.6× 89 1.1k
Dulabh Monga United States 15 539 0.9× 396 1.3× 128 0.5× 119 0.5× 135 0.8× 74 1.1k
Glenwood D. Goss Canada 20 541 0.9× 526 1.7× 253 1.1× 396 1.7× 90 0.5× 39 1.2k
Kim A. Reiss United States 19 971 1.6× 452 1.4× 189 0.8× 444 1.9× 135 0.8× 63 1.4k
Arturo Loaiza‐Bonilla United States 13 523 0.8× 287 0.9× 241 1.0× 262 1.1× 78 0.5× 62 960

Countries citing papers authored by Jeroen Dekervel

Since Specialization
Citations

This map shows the geographic impact of Jeroen Dekervel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeroen Dekervel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeroen Dekervel more than expected).

Fields of papers citing papers by Jeroen Dekervel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeroen Dekervel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeroen Dekervel. The network helps show where Jeroen Dekervel may publish in the future.

Co-authorship network of co-authors of Jeroen Dekervel

This figure shows the co-authorship network connecting the top 25 collaborators of Jeroen Dekervel. A scholar is included among the top collaborators of Jeroen Dekervel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeroen Dekervel. Jeroen Dekervel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laenen, Annouschka, Jeroen Dekervel, Diethard Monbaliu, et al.. (2025). Long-Term Outcome of Liver Transplantation for Hepatocellular Carcinoma After Bridging or Downstaging with Doxorubicin-Eluting Superabsorbent Polymer Microspheres. CardioVascular and Interventional Radiology. 48(4). 472–484.
2.
3.
Dekervel, Jeroen, et al.. (2025). Breath- and blood-based molecular assessment for gastroesophageal cancer. PubMed. 7. 100132–100132. 1 indexed citations
4.
Deroose, Christophe M., Chris Verslype, Diethard Monbaliu, et al.. (2024). Resin-Based Yttrium-90 Radioembolization as a Bridging or Downstaging Treatment to Liver Transplantation for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology. 36(2). 282–292. 2 indexed citations
5.
Pauwels, Elin, Timon Vandamme, Willem Lybaert, et al.. (2024). Clinical impact of using [ 18 F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ 68 Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial. Journal of Neuroendocrinology. 36(8). e13420–e13420. 4 indexed citations
6.
7.
Cappuyns, Sarah, et al.. (2024). Applications of single-cell multi-omics in liver cancer. JHEP Reports. 6(7). 101094–101094. 6 indexed citations
8.
Cutsem, Eric Van, Julien Taı̈eb, Rona Yaeger, et al.. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. 41(14). 2628–2637. 63 indexed citations
9.
Jauregui-Amezaga, Aranzazu, Sandrine Aspeslagh, Jeroen Dekervel, et al.. (2023). Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. European Journal of Cancer. 187. 36–57. 6 indexed citations
10.
Cappuyns, Sarah, Vincent Vandecaveye, Bram Boeckx, et al.. (2023). PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nature Communications. 14(1). 7825–7825. 33 indexed citations
11.
Kinget, Lisa, et al.. (2023). Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers. 15(2). 348–348. 14 indexed citations
12.
Debucquoy, Annelies, Eva Oldenburger, Chantal Van Audenhove, et al.. (2023). Development of a Patient Decision Aid for Rectal Cancer Patients with Clinical Complete Response after Neo-Adjuvant Treatment. Cancers. 15(3). 806–806. 5 indexed citations
13.
Pauwels, Elin, Vincent Vandecaveye, Wies Deckers, et al.. (2023). Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Research. 13(1). 53–53. 9 indexed citations
14.
Debucquoy, Annelies, Ines Joye, André D’Hoore, et al.. (2022). Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study. Clinical and Translational Radiation Oncology. 36. 113–120. 11 indexed citations
15.
Pauwels, Elin, Jeroen Dekervel, Chris Verslype, et al.. (2022). [68Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [177Lu]Lu-DOTATATE PRRT.. PubMed. 12(5). 152–162. 11 indexed citations
16.
Goffin, Karolien, Jeroen Dekervel, Kristof Baete, et al.. (2021). Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers. 14(1). 129–129. 30 indexed citations
17.
18.
Dekervel, Jeroen, Petra Windmolders, Diether Lambrechts, et al.. (2016). Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response. Translational Oncology. 10(1). 59–69. 40 indexed citations
19.
Amini‐Bavil‐Olyaee, Samad, Jeroen Dekervel, Chris Verslype, et al.. (2015). A rare case of HBV genotype fluctuation (shifting and reversion) after liver transplantation. Journal of Clinical Virology. 71. 93–97. 6 indexed citations
20.
Dekervel, Jeroen, Daphne Hompes, Hannah van Malenstein, et al.. (2014). Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients. Clinical Cancer Research. 20(8). 2159–2168. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yusuke Mitsunori Breakdown of academic impact, for papers by Roberto Carmagnani Pestana Breakdown of academic impact, for papers by Xinyu Bi Breakdown of academic impact, for papers by Bin Meng Breakdown of academic impact, for papers by Antonella Argentiero Breakdown of academic impact, for papers by Susanna V. Ulahannan Breakdown of academic impact, for papers by Dulabh Monga Breakdown of academic impact, for papers by Glenwood D. Goss Breakdown of academic impact, for papers by Kim A. Reiss Breakdown of academic impact, for papers by Arturo Loaiza‐Bonilla
Rankless by CCL
2026